Clinical-stage Therapeutics Company Presents Positive Clinical Trial Results

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently presented promising data from their ReSPECT-LM clinical trial at the 2024 Society for Neuro-Oncology (SNO) and American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The trial focuses on evaluating the safety and efficacy of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for treating leptomeningeal disease (LM), a severe complication of various cancers. $Plus Therapeutics (PSTV.US)$